Kcentra regulatory update

CSL said the Centers for Medicare and Medicaid Services (CMS) will provide hospitals with additional reimbursement payments beyond the predetermined standard rates for the use of Kcentra in an inpatient setting for the urgent reversal of warfarin therapy in adults with acute major bleeding. The additional payments are part of CMS's technology add-on payment (NTAP) program, which was initiated in 2001 to provide additional reimbursement for innovative therapies that incur more costs than can be covered by the standard reimbursement rates. Beginning Oct. 1, hospitals will receive additional payments of up to 50% of the cost of Kcentra, or up to $1,587.50, for cases involving Kcentra that exceed the payment amount under the Medicare Severity Diagnosis-Related Groups (MS-DRGs). The add-on payment will continue for at least 2 years. ...